ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -196.47 Million EUR | -1093.47% |
| 2022 | 19.77 Million EUR | 372.82% |
| 2021 | -7.24 Million EUR | -254.69% |
| 2020 | 4.68 Million EUR | -57.31% |
| 2019 | 10.97 Million EUR | 278.03% |
| 2018 | 2.9 Million EUR | 279.37% |
| 2017 | -1.61 Million EUR | 70.09% |
| 2016 | -5.41 Million EUR | -264.28% |
| 2015 | 3.29 Million EUR | 279.19% |
| 2014 | 868.96 Thousand EUR | 247.85% |
| 2013 | -587.71 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -111.17 Million EUR | 0.0% |
| 2023 Q2 | -79.69 Million EUR | 0.0% |
| 2023 FY | -196.47 Million EUR | -1093.47% |
| 2023 Q4 | -196.47 Million EUR | 0.0% |
| 2022 Q4 | 19.77 Million EUR | 0.0% |
| 2022 Q2 | 22.9 Million EUR | 0.0% |
| 2022 FY | 19.77 Million EUR | 372.82% |
| 2021 FY | -7.24 Million EUR | -254.69% |
| 2021 Q4 | -7.24 Million EUR | 0.0% |
| 2021 Q2 | 27.46 Million EUR | 0.0% |
| 2020 Q4 | 4.68 Million EUR | 0.0% |
| 2020 Q2 | 12.43 Million EUR | 0.0% |
| 2020 FY | 4.68 Million EUR | -57.31% |
| 2019 FY | 10.97 Million EUR | 278.03% |
| 2019 Q2 | 10.25 Million EUR | 0.0% |
| 2019 Q4 | 10.97 Million EUR | 0.0% |
| 2018 Q2 | -2.57 Million EUR | 0.0% |
| 2018 FY | 2.9 Million EUR | 279.37% |
| 2018 Q4 | 2.9 Million EUR | 0.0% |
| 2017 Q2 | -945 Thousand EUR | 0.0% |
| 2017 FY | -1.61 Million EUR | 70.09% |
| 2017 Q4 | -1.61 Million EUR | 0.0% |
| 2016 Q4 | -7.62 Million EUR | 0.0% |
| 2016 Q2 | -715 Thousand EUR | 0.0% |
| 2016 FY | -5.41 Million EUR | -264.28% |
| 2015 Q2 | -53.1 Million EUR | 0.0% |
| 2015 Q4 | 286 Thousand EUR | 0.0% |
| 2015 FY | 3.29 Million EUR | 279.19% |
| 2014 Q3 | -1221.00 EUR | 0.0% |
| 2014 FY | 868.96 Thousand EUR | 247.85% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 868.96 Thousand EUR | 71267.98% |
| 2013 FY | -587.71 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -27417.927% |
| Adocia SA | 127 Thousand EUR | 154807.087% |
| Aelis Farma SA | -16.19 Million EUR | -1113.426% |
| Biophytis S.A. | 2.7 Million EUR | 7368.886% |
| Advicenne S.A. | 12.17 Million EUR | 1713.782% |
| genOway Société anonyme | 2.97 Million EUR | 6708.814% |
| IntegraGen SA | -709.74 Thousand EUR | -27582.744% |
| Medesis Pharma S.A. | 1.15 Million EUR | 17063.936% |
| Neovacs S.A. | -237.08 Thousand EUR | -82771.688% |
| NFL Biosciences SA | -2.27 Million EUR | -8533.094% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 4609.987% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -23556.429% |
| Sensorion SA | 1.37 Million EUR | 14355.904% |
| Theranexus Société Anonyme | 2.44 Million EUR | 8138.688% |
| TME Pharma N.V. | -1.07 Million EUR | -18109.268% |
| Valbiotis SA | -18.13 Million EUR | -983.18% |
| TheraVet SA | 12.78 Thousand EUR | 1536885.295% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 9112.752% |
| argenx SE | -1.83 Billion EUR | 89.302% |
| BioSenic S.A. | 28.04 Million EUR | 800.606% |
| Celyad Oncology SA | -6.1 Million EUR | -3119.895% |
| DBV Technologies S.A. | -114.95 Million USD | -70.916% |
| Galapagos NV | -157.2 Million EUR | -24.98% |
| Genfit S.A. | -7.61 Million EUR | -2481.5% |
| GeNeuro SA | 5.91 Million EUR | 3424.276% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | -682.407% |
| Innate Pharma S.A. | -30.71 Million EUR | -539.743% |
| Inventiva S.A. | 10.48 Million EUR | 1973.181% |
| MaaT Pharma SA | -10.2 Million EUR | -1825.311% |
| MedinCell S.A. | 39.5 Million EUR | 597.4% |
| Nanobiotix S.A. | -24.71 Million EUR | -694.878% |
| Onward Medical N.V. | -12.89 Million EUR | -1423.794% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 13836.512% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 824.236% |
| Oxurion NV | 10.71 Million EUR | 1934.528% |
| Pharming Group N.V. | 99.4 Million EUR | 297.661% |
| Poxel S.A. | 44.55 Million EUR | 540.939% |
| GenSight Biologics S.A. | 16.29 Million EUR | 1305.83% |
| Transgene SA | -14.4 Million EUR | -1263.578% |
| Financière de Tubize SA | 78.62 Million EUR | 349.892% |
| UCB SA | 2.17 Billion EUR | 109.025% |
| Valneva SE | 82.73 Million EUR | 337.476% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -960.667% |